Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study

Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study

BackgroundInterleukin-13 receptor α 2 (IL13Rα2) is a promising tumor-directed antigen of malignant glioma (MG). Here, we examine the efficacy and safety of T cells containing a YYB-103 chimeric antigen receptor (CAR) that can preferentially bind to IL13Rα2 on MG cells.MethodsIL13 was modified on the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kiwan Kim, Ho-Shin Gwak, Nayoung Han, Eun Kyung Hong, Beom K. Choi, Sangeun Lee, Soyoung Choi, Ju-Hwang Park, Ji-Hye Seok, Yeongha Jeon, Hyuntae Cho, Song-Jae Lee, Yura Lee, Ki Taek Nam, Seong-Won Song
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
chimeric antigen receptor T cell
immunohistochemistry
interleukin-13
malignant glioma
immunotherapy
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/dc3012fd96854bd3994a62b55e0a09fb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/dc3012fd96854bd3994a62b55e0a09fb

Ejemplares similares